You are browsing articles on the topic of Electrophysiology Archives - CardioExchange

Avatar of Manesh R. Patel, MD

Digoxin Use in Afib: Revisiting Data from ROCKET AF (9 Apr 2015)

Voices

Manesh R. Patel, MD

Manesh R. Patel discusses his research group’s retrospective analysis of data on digoxin use among patients with atrial fibrillation in the ROCKET AF trial.

Avatar of Larry Husten, PHD

Cardiac Arrest During Exercise in Middle-Aged People (6 Apr 2015)

News

Dropping dead while exercising is a common fear, especially among middle-aged men. Unfortunately there have been limited data on the precise rate of sudden cardiac arrest (SCA) in middle-aged people and little understanding about the medical history of the victims of SCA. Now a new study fills in some important gaps in knowledge and shows that this…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Dangerous Interaction: New Hepatitis C Drug and Old Arrhythmia Drug (23 Mar 2015)

News

Late last week Gilead Sciences issued a warning about a rare but potentially fatal interaction between its stellar new hepatitis C drug sofosbuvir and amiodarone, a potent but tricky antiarrhythmic agent. Sofosbuvir is marketed as Sovaldi and, in combination with another antiviral agent, as Harvoni. Amiodarone is a class III antiarrhythmic with a number of…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Joseph

To Shock or Not to Shock — That Is the Question (4 Feb 2015)

Voices

Joseph G Akar, MD/PhD and Jehad Al Buraiki, MD

Jehad Al Buraiki and Joseph G. Akar offer differing perspectives, from each side of the Atlantic, on cardiac resynchronization-pacemaker therapy.

Avatar of Jonathan

How Accurately Do ICD-9 Codes Identify Strokes in Patients with Atrial Fibrillation? (22 Jan 2015)

Voices

Jonathan L. Thigpen, PharmD

Jonathan L. Thigpen discusses his research group’s assessment of the validity of ICD-9 codes in identifying strokes in patients with atrial fibrillation.

Avatar of Larry Husten, PHD

Study Suggests Epinephrine for Cardiac Arrest May Be Harmful (1 Dec 2014)

News

Epinephrine has been a cornerstone of therapy during cardiac resuscitation after cardiac arrest because of its well-established ability to stimulate the heart and increase the probability of a return of spontaneous circulation (ROSC). In recent years, however, concerns have been raised that people treated with epinephrine may have worse neurological outcomes following their resuscitation. In…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

European Review Confirms Increased Risk with Ivabradine (24 Nov 2014)

News

Following a review provoked by troubling findings that emerged from a large clinical trial, the European Medicines Agency (EMA) is making several recommendations intended to lower the risk of heart problems linked to the heart-rate-lowering drug ivabradine. The drug is marketed by Servier in Europe under the brand names of Corlentor and Procoralan and is indicated for…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

AF Patients at Increased Risk for Silent Strokes (3 Nov 2014)

News

The increased risk of stroke in people with atrial fibrillation (AF) is well known, and this stroke risk is, of course, linked to an increased risk of cognitive impairment and dementia. Less well known is that people with AF have an increased risk for cognitive impairment independent of their stroke risk. Now a new study…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Advisory Panel Gives Tepid Support to New Anticoagulant (31 Oct 2014)

News

On Thursday the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 9-1 in favor of approval for Daiichi Sankyo’s edoxaban (Savaysa). The outcome will likely result in a drug that will be on the market, but that few physicians will prescribe until further studies are performed. Edoxaban will almost certainly become the fourth new oral anticoagulant (NOAC)…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Panel Gives Cautious Endorsement to Novel Boston Scientific Device (9 Oct 2014)

News

The FDA’s Circulatory System Devices advisory panel gave an extremely cautious endorsement on Wednesday to Boston Scientific’s Watchman device, a novel catheter-delivered left atrial appendage closure device for people with atrial fibrillation. They signaled that although they thought the device should be made available they also thought that there should be significant restrictions on its use. The panel wrestled…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.